已收盤 12-12 16:00:00 美东时间
-0.020
-0.10%
Morningstar DBRS flagged a mixed 2026 outlook for business development companies, contending a growing deal pipeline should support growth but expectations of further interest-rate cuts could weigh on...
12-14 05:05
Ares Capital ( ($ARCC) ) has shared an announcement. On December 3, 2025, Ares ...
12-10 06:48
最高股息率超11%!泰森食品、惠普、英美烟草等超100家高分红股如何布局!投资者可在除息前布局,赚取股息!一文速览派息名单>>
12-01 14:00
据华尔街日报:包括阿波罗和阿瑞斯在内的资产管理公司因涉嫌信贷市场垄断而被起诉。美国电信公司Optimum就合作协议起诉其贷款方,这标志着杠杆借款人首次发起此类反...
11-26 04:24
Blue Owl Capital Inc. (OWL) may revive its plan to merge two of its private credit funds, if Blue Owl Capital Corp. (OBDC) shares improve enough so they're not trading at a discount to net asset value...
11-24 22:59
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据ARS Pharmaceuticals (SPRY) 2025年第三季度业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - 总营收:3,250万美元,其中包括美国Neffy净产品收入3,130万美元、合作伙伴供应收入110万美元、德国YERNEPI相关版税收入10万美元 - 美国Neffy净产品收入:3,130万美元,超出市场预期的2,830万美元 - 版税收入按GAAP准则计入资产负债表融资负债项,未计入损益表 **盈利状况:** - 2025年年初至今净亏损:5,120万美元,每股亏损0.52美元 - 研发费用
11-11 12:37
Kayne Anderson BDC (KBDC) declares $0.40/share quarterly dividend, in line with previous. Forward yield 11.18% Payable Jan. 16; for shareholders of record Dec. 31; ex-div Dec. 31. See KBDC Dividend Sc...
11-11 06:38
Kayne Anderson BDC press release (KBDC): Q3 Total investment income for the quarter ended September 30, 2025 was $61.3 million, as compared to $57.3 million for the quarter ended June 30, 2025. Net i...
11-11 05:26
In a world where yield is scarce and volatility has become a feature rather tha...
11-04 00:44